Investigational drug · Phase 3
ABP 938
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Neovascular Age-related Macular Degeneration, nAMD.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
3
Any phase or sponsor naming "ABP 938"
First trial start
2026
May 27, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "ABP 938", any sponsor or status.
Conditions studied
As listed on its trial records.
- Neovascular Age-related Macular Degeneration
- nAMD
Approved drugs for the same conditions: Wet macular degeneration · Ophthalmology
Largest trials
Live from ClinicalTrials.gov: studies naming "ABP 938" as an intervention, largest first.
- A Study to Understand Effectiveness and Safety of ABP 938 Compared to Aflibercept (Eylea®) in Patients Suffering With Neovascular Age-related Macular Degeneration [Neovascular (Wet) AMD]Pivotal-lookingCompleted
AmgenAmgen (AMGN)
NCT04270747 · 576 participants · Start Jun 22, 2020 · Primary completion Jul 18, 2022
Drug: ABP 938; Aflibercept · For: Neovascular (Wet) Age-related Macular Degeneration (AMD)
Sites: Phoenix, Arizona; Fullerton, California; La Jolla, California · 118 sites in all
- A Study to Evaluate Efficacy, Safety, and Immunogenicity With ABP 938 8 mg Versus EYLEA® HD (Aflibercept) in Participants With Neovascular Age-related Macular DegenerationPivotal-lookingRecruiting
AmgenAmgen (AMGN)
NCT07614776 · 304 participants (planned) · Start May 27, 2026 · Primary completion Jul 31, 2027
Drug: ABP 938 8 mg; Aflibercept (US) 8 mg · For: Neovascular Age-related Macular Degeneration; nAMD
Sites: Fullerton, California; Long Beach, California; Modesto, California · 101 sites in all
- A Study to Evaluate ABP 938 and Aflibercept (Eylea®) in Participants With Chorioretinal Vascular Disease (CVD)Pivotal-lookingCompleted
AmgenAmgen (AMGN)
NCT05704725 · 49 participants · Start Jan 23, 2023 · Primary completion Feb 17, 2023
Drug: ABP 938; Aflibercept · For: Chorioretinal Vascular Disease
Sites: Austin, Texas; Bellaire, Texas; San Antonio, Texas · 4 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Real-World Utilization and Initial Experience with Aflibercept-ayyh (PAVBLU®) for Retinal Disorders in United States Retina Practices: A Descriptive Retrospective Analysis.
Servin AE, McFadden I, Esmaeilkhanian H, et al. · Ophthalmol Ther 2026
- Anti-Vascular Endothelial Growth Factor Biosimilars for Use in the Aging Eye.
Sharma A, Sheth JU, Kuppermann BD · Drugs Aging 2026
- Efficacy and safety of aflibercept biosimilars compared to aflibercept in the treatment of neovascular age-related macular degeneration: a systematic review and meta-analysis.
Zhou Y, Zhan Z, Wang Z, et al. · Front Pharmacol 2026
- Randomized Trial of Biosimilar ABP 938 Compared with Reference Aflibercept in Adults with Neovascular Age-Related Macular Degeneration.
Friedman S, London N, Hamouz J, et al. · Ophthalmol Retina 2026
- Re: Friedman et al: Randomized trial of biosimilar ABP 938 compared with reference aflibercept in adults with neovascular age-related macular degeneration (2025 Aug 5:S2468-6530(25)00351-3. doi: 10.1016/j.oret.2025.07.015. Online ahead of print.).
Lou J, Liao X · Ophthalmol Retina 2026
- Nonclinical Similarity of the Biosimilar Candidate ABP 938 with Aflibercept Reference Product.
Seo N, Kuhns S, Andrews DA, et al. · Ophthalmol Ther 2025
Also in development for Neovascular Age-related Macular Degeneration
- OTX-TKIaxitinib implantPhase 33 trials
Ocular Therapeutix, Inc. · Neovascular Age-related Macular Degeneration, Neovascular Age-Related Macular Degeneration, Neovascular Age-Related Macular Degeneration (nAMD)
- IBI302Phase 32 trials
Innovent Biologics (Suzhou) Co. Ltd. · Neovascular Age-related Macular Degeneration, Diabetic Macular Oedema
- Surabgene LomparvovecABBV-RGX-314Phase 32 trials
AbbVie · Diabetic Retinopathy, Neovascular Age-related Macular Degeneration
- ASKG712AM712, VIS-101Phase 21 trial
Visara, Inc. · Neovascular Age-related Macular Degeneration
- RRG001Phase 21 trial
Shanghai Refreshgene Technology Co., Ltd. · Neovascular Age-related Macular Degeneration
- SAR402663Phase 21 trial
Sanofi · Neovascular Age-related Macular Degeneration
- SYL1801Phase 21 trial
Sylentis, S.A. · Wet Macular Degeneration, Neovascular Age-related Macular Degeneration, Macular Degeneration
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Amgen.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.